Hospital Universitario Austral - Pilar
Hospital Universitario Austral - Pilar
Av. Juan Domingo Perón 1500, Pilar, Buenos Aires
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Silvio Carricondo
Miguel Manglio Rizzo
Nicolás Minatta
José Ignacio Trucco
Gustavo Daniel Kusminsky
Sofia Blotta
Pablo Maid
Luis Ignacio Daverede
Andrés Nicolás Atamañuk
Hernán Amartino
Marcelo Silva
Cristina Alonso
Diego Arufe
Gabriela Marinsalta
David Veron
Open studies
Lung cancer
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) - DeLLphi-306 - AmgenSee more
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) - ARTEMIDE-Lung02 - AstraZenecaSee more
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC - ARTEMIDE-Lung03 - AstraZenecaSee more
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) - KRYSTAL-4 - Mirati Therapeutics Inc.See more
Fatty liver/nash
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis - Kowa Research Institute, Inc.See more
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.See more
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) - ENLIGHTEN-Fibrosis - 89bio, Inc.See more
Myeloproliferative syndromes
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment - MYF3001 - Geron CorporationSee more
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) - MK-3543-006 - Merck Sharp & Dohme LLCSee more
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) - MK-3543-007 - Merck Sharp & Dohme LLCSee more
Multiple myeloma
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma - EXCALIBER Maintenance - Bristol-Myers SquibbSee more
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) - MagnetisMM-32 - PfizerSee more
Steatohepatitis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.See more
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) - ENLIGHTEN-Fibrosis - 89bio, Inc.See more
Cholangitis
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis - ELFIDENCE - IpsenSee more
Cirrhosis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.See more
Fatty Liver
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis - Kowa Research Institute, Inc.See more
Lupus
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus - POETYK SLE-2 - Bristol-Myers SquibbSee more
Non-Hodgkin Lymphoma
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) - waveLINE-010 - Merck Sharp & Dohme LLCSee more
